MapLight Therapeutics

Edit info

Founded: 2018

Location: Boston, MA

Employee range: 11 - 50

Clinical stage: Clin2

Therapy area: Autism spectrum disorder

Drug types: NEU, PSY

Lead product: ML-004

Funding: 10-100M

maplightrx.com

linkedin.com

job board

Drug notes:

ML-007 Clin1 dyskinesias. Clin1 schizophrenia; ML-016 RD/Clin0 depression; ML-009 RD/Clin0 hyperactivity/impulsivity; ML-105 RD depression

About:

MapLight Therapeutics is developing novel therapeutics for patients with disorders of the central nervous system. Given the complexity of the brain, diseases with highly specific symptoms should be treated with the same therapeutics. MapLight is using the combination of transcriptomics, optogenetics and STARmap to develop a strong pipeline of safe, effective therapeutics. Optogenetics is used to identify key cell types, transcriptomics is to find targets and STARmap is used to visualize neural circuits. MapLight has already brought two novel therapeutics to the clinic, with more on the horizon.